Castle Biosciences Inc (CSTL) — Strategic Asset Allocation Index
Castle Biosciences Inc (CSTL) has a Strategic Asset Allocation Index of 1.3% as of March 2025. Strategic assets (PP&E of $- plus long-term investments of $5.57 Million) total $5.57 Million, measured against net assets of $440.31 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Castle Biosciences Inc Strategic Asset Allocation Index (2019–2022)
This chart shows how Castle Biosciences Inc's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of March 2025, the index stands at 1.3%, representing strategic assets of $5.57 Million against net assets of $440.31 Million USD. Explore Castle Biosciences Inc cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Castle Biosciences Inc (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Castle Biosciences Inc from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see CSTL stock market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 6.6% | $26.50 Million | $26.50 Million | $- | $399.15 Million | ▲ +2.5 pp |
| 2021 | 4.1% | $16.88 Million | $16.88 Million | $- | $411.74 Million | ▲ +2.4 pp |
| 2020 | 1.7% | $7.10 Million | $7.10 Million | $- | $415.69 Million | ▼ -0.7 pp |
| 2019 | 2.4% | $2.06 Million | $2.06 Million | $- | $85.11 Million | — |